The Experts below are selected from a list of 219 Experts worldwide ranked by ideXlab platform
Pedro Lloret - One of the best experts on this subject based on the ideXlab platform.
-
Topical imiquimod for Bowenoid Papulosis in an HIV-positive woman.
Acta dermato-venereologica, 2002Co-Authors: Pedro Redondo, Pedro LloretAbstract:Sir, CASE REPORT Bowenoid Papulosis consists clinically of multiple verruA 36-year-old woman presented with perianal and gencoid papules, usually situated in the anogenital region ital skin lesions of 6 years’ duration. The patient’s HIV-1 of young men and women. Histologically, it is an in situ infection had been diagnosed approximately 10 years squamous cell carcinoma (1) and is most commonly earlier, and had been well controlled during most of associated with high-risk oncogenic genotypes of human that time with antiviral therapy. The patient’s viral load papillomavirus (HPV ) types 16, 18, 33 and 39 (2, 3). and CD4 levels were 50 copies/ml and 750/mm3 , respectBowenoid Papulosis usually follows a benign course and ively. She had received previous treatment with cryomay spontaneously resolve in immunocompetent therapy and local excision with electrocoagulation, with patients. In older women and immunocompromised relapses. Physical examination revealed perianal and patients it generally persists and may progress to an perivulvar red plaques covered with warty papules invasive squamous cell carcinoma. Conventional treat(Fig. 1A). Histological specimens con rmed the clinical ments include local excision, electrocoagulation, elecdiagnosis of Bowenoid Papulosis. Topical treatment with trodessication, cryosurgery, laser removal and topical imiquimod 5% cream was proposed. The patient applied 5- uorouracil. Imiquimod, an imidazoquinoline amine, the cream at bedtime on the aVected areas. Tolerance is an immune response modi er recently approved for was good, with initial irritation and burning during the the topical treatment of external genitalia and perianal rst 2 weeks. After one month of treatment, spectacular warts (4). Imiquimod exhibits antiviral and antitumour improvement was achieved, vulvar aVection disappeared eVects in vivo through induction of cytokines and and perianal lesion accomplished remarkable clinical enhancement of cell-mediated cytolytic antiviral activity. remission (Fig. 1B). The patient refused a further biopsy In the following, topical imiquimod was used in a human to con rm the absence of histological lesions. At that immunode ciency virus (HIV) infected woman with perianal and perivulvar Bowenoid Papulosis. moment, the patient discontinued treatment. Two
Ma Jun-hong - One of the best experts on this subject based on the ideXlab platform.
-
Expression of survivin in skin lesions of condyloma acuminatum,Bowenoid Papulosis,Bowen's disease and squamous cell carcinoma
Journal of Shanxi Medical University, 2008Co-Authors: Ma Jun-hongAbstract:Objective To investigate the expression of survivin in patients with condyloma acuminatum,Bowenoid Papulosis,Bowen's disease and squamous cell carcinoma,and to explore its possible clinical significance.Methods Survivin expression was detected in normal tissues(n=18),condyloma acuminatum(n=37),Bowenoid Papulosis(n=26),Bowen's disease(n=24) and squamous cell carcinoma(n=25)by immunohistochemistry technique.Histopathological changes were observed in patients with Bowenoid Papulosis or Bowen's disease.Results The expression of survivin increased successively from normal tissue,condyloma acuminatum,Bowenoid Papulosis to squamous cell carcinoma(P0.05).The expression of survivin was significantly lower in Bowen's disease than that in squamous cell carcinoma(P0.05),but it was not significant different between those in Bowen's disease and Bowenoid Papulosis(P0.05).Histopathologically,the degree of cell atypia was significantly higher in Bowen's disease than in Bowenoid Papulosis.Conclusion The results suggest that the expression of survivin may play an important role in both cell proliferation and immortalization.
Kang Zeng - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic evaluation of 5-aminolevulinic acid-mediated photodynamic therapy in Bowenoid Papulosis.
Photodiagnosis and photodynamic therapy, 2019Co-Authors: Qilei Che, Jingying Wang, Qi Wang, Lifen Jiang, Hui Liu, Mei Zhang, Kang ZengAbstract:Abstract Background Bowenoid Papulosis is a polymorphic papular disease that occurs on the external genital area. We investigated the efficacy of 5-aminolevulinic acid-mediated photodynamic therapyin the treatment of Bowenoid Papulosis. Methods We investigated 200 Bowenoid Papulosis cases from the Department of Dermatology and Venereology of Nanfang Hospital in 2016–2018. Biopsies were performed from Bowenoid Papulosis lesions before treatment. The patients were divided into two groups: 100 patients each in the 5-aminolevulinic acid-mediated photodynamic therapy and control groups(radiofrequency cauterisation, microwave ablation, and surgical resection groups). Differences in lesion clearance, recurrence rate, and patient satisfaction after treatment were evaluated. Results Photodynamic therapy sessions for multifocal Bowenoid Papulosis were more frequent than those for monofocal lesions. All lesions in the 5-aminolevulinic acid-mediated photodynamic therapy group were cleared after photodynamic therapy, with no recurrence at the 1-year follow-up; however, 20 (20.0 %) patients in the control showed recurrence after 1 year. Only 5patients in the photodynamic group were unsatisfied with the treatment cost and 34 patients in the control group experienced short-term pain and scarring. The recurrence rate was significantly lower (P Conclusions 5-aminolevulinic acid-mediated photodynamic therapy for Bowenoid Papulosis results in a low recurrence rate and high satisfaction.
Darrell J. Fader - One of the best experts on this subject based on the ideXlab platform.
-
Isolated extragenital HPV-thirties-group-positive Bowenoid Papulosis in an AIDS patient.
The British journal of dermatology, 2006Co-Authors: Darrell J. Fader, M.h. Stoler, Thomas F. AndersonAbstract:The term 'Bowenoid Papulosis' (BP) was introduced in 1978 to describe multiple verrucous papules on the genitalia with a histological resemblance to Bowen's disease and a clinical resemblance to condylomata. ' BP is primarily a disease of sexually active young people, with a mean age of onset of about 30 years.' Multiple 2-10 mm red-brown or violaceous papules, some with a verrucous surface, may coalesce into plaques. The clinical spectrum includes lichenoid papules, erythematous macules and 'leukoplakia-Iike' lesions.^ •* BP occurs most frequently on the genitalia, perianal skin or crural regions, and there is a slight female predilection.^"* There are rare reports of extragenital BP with concomitant genital involvement. Histologically, BP exhibits many features of Bowen's disease: crowded, pleomorphic 'windblown' keratinocyte nuclei with occasional mitotic figures, and cytological atypia, which is usually less pronounced than in Bowen's disease.' '* Viral features are characteristically absent on routine haematoxylin and eosin-stained sections, although BP is caused by a human papillomavirus. In essence, cutaneous and genital BP are HPV-induced mild, moderate, or severe degrees of intraepithelial dysplasia. We describe an AIDS patient with isolated extragenital Bowenoid Papulosis. In situ hybridization studies revealed an unusual HPV subtype.
-
Isolated extragenital Bowenoid Papulosis of the neck.
Journal of the American Academy of Dermatology, 1999Co-Authors: Timothy M. Johnson, Anita Saluja, Darrell J. Fader, David Blum, Jenny Cotton, Timothy S. Wang, Lori LoweAbstract:We report a case of extragenital Bowenoid Papulosis (BP) in a healthy immunocompetent 42-year-old man. The lesions occurred on the anterolateral aspects of the neck and were not associated with genital, oral, or periungual lesions. Lesional skin tested positive with the Digene hybrid capture system cocktail assay that identifies infection with a mixture of high to intermediate oncogenic human papillomavirus (HPV) types, including types 16, 18, 31, 33, 35, 45, 51, 52, and 56. This cocktail assay identifies infection with HPV types typically associated with high-grade squamous intraepithelial lesions and invasive carcinoma. This case represents the sixth case of isolated cutaneous BP occurring a significant distance from the genital region.
Pedro Redondo - One of the best experts on this subject based on the ideXlab platform.
-
Topical imiquimod for Bowenoid Papulosis in an HIV-positive woman.
Acta dermato-venereologica, 2002Co-Authors: Pedro Redondo, Pedro LloretAbstract:Sir, CASE REPORT Bowenoid Papulosis consists clinically of multiple verruA 36-year-old woman presented with perianal and gencoid papules, usually situated in the anogenital region ital skin lesions of 6 years’ duration. The patient’s HIV-1 of young men and women. Histologically, it is an in situ infection had been diagnosed approximately 10 years squamous cell carcinoma (1) and is most commonly earlier, and had been well controlled during most of associated with high-risk oncogenic genotypes of human that time with antiviral therapy. The patient’s viral load papillomavirus (HPV ) types 16, 18, 33 and 39 (2, 3). and CD4 levels were 50 copies/ml and 750/mm3 , respectBowenoid Papulosis usually follows a benign course and ively. She had received previous treatment with cryomay spontaneously resolve in immunocompetent therapy and local excision with electrocoagulation, with patients. In older women and immunocompromised relapses. Physical examination revealed perianal and patients it generally persists and may progress to an perivulvar red plaques covered with warty papules invasive squamous cell carcinoma. Conventional treat(Fig. 1A). Histological specimens con rmed the clinical ments include local excision, electrocoagulation, elecdiagnosis of Bowenoid Papulosis. Topical treatment with trodessication, cryosurgery, laser removal and topical imiquimod 5% cream was proposed. The patient applied 5- uorouracil. Imiquimod, an imidazoquinoline amine, the cream at bedtime on the aVected areas. Tolerance is an immune response modi er recently approved for was good, with initial irritation and burning during the the topical treatment of external genitalia and perianal rst 2 weeks. After one month of treatment, spectacular warts (4). Imiquimod exhibits antiviral and antitumour improvement was achieved, vulvar aVection disappeared eVects in vivo through induction of cytokines and and perianal lesion accomplished remarkable clinical enhancement of cell-mediated cytolytic antiviral activity. remission (Fig. 1B). The patient refused a further biopsy In the following, topical imiquimod was used in a human to con rm the absence of histological lesions. At that immunode ciency virus (HIV) infected woman with perianal and perivulvar Bowenoid Papulosis. moment, the patient discontinued treatment. Two